Tricor

Revenue is seen rising 7.3 percent to Rs 3,375.6 crore in quarter ended December 2015 compared to Rs 3,144.9 crore in year-ago period, driven by domestic business but impacted by US business.

Lupin Q3 PAT may grow 35% to Rs 452 cr but margin may dip

According to CNBC-TV18 poll, analysts expect profit after tax at Rs 452 crore as against Rs 335 crore and revenue at Rs 2,848 crore versus Rs 2,501 crore year-on-year.

Lupin Q1: Analysts expect PAT to grow 33% at Rs 373 cr

Lupin's revenues may increase by 19 percent on yearly basis to Rs 2,674 crore during April-June quarter. Previous quarter (Q4) was the 26th consecutive quarter of revenue growth of over 15 percent Y-o-Y.

Why Credit Suisse is neutral on Lupin despite mkt thumbs-up

Lupin is up nearly 7 percent in last five trading sessions and about 35 percent this year in an overall weak market.

Lupin falls; Mylan launches cholesterol drug

Mylan Inc said in a statement on Friday its unit Mylan Pharmaceuticals Inc has shipped generic Tricor, or fenofibrate tablets, of 48 mg and 145 mg. Mylan compete against Lupin, which also sells generic versions of Tricor.

Bullish on Glenmark, Ipca Labs among midcaps: Antique

In an interview to CNBC-TV18, Anmol Ganjoo of Antique Broking share outlook on the pharmaceutical space and trading strategies for various stocks in the sector. He is bullish on Glenmark and Ipca laboratories from the midcap pharma space.

Lupin launches generic TriCor in US

Drug firm Lupin has launched generic version of Tricor, an anti-cholesterol drug, in the US market after getting approval from the US Food and Drug Administration (USFDA).

About 30% products will be impacted by price control: Lupin

Mumbai based pharma company Lupin says any kind of price control will be a deterrent for the industry and 30 percent of its portfolio will be impacted if government implements price control measures.